The finding suggests that the switch from insulin therapy to GLP-1 receptor agonist therapy can be done in patients with T2D who are younger and have a relatively low dose of insulin and with relatively high postprandial glucose levels even if they have higher HbA1c levels upon changing to dulaglutide. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.